| Name | Title | Contact Details |
|---|---|---|
Jeffery Brinza |
Chief Administrative Officer and General Counsel | Profile |
Tamara Joseph |
General Counsel and Corporate Secretary | Profile |
Evolution Medical Communications, LLC is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.